Cancer cachexia is a multifactor syndrome involving multiple systems in the whole body. It is manifested in the loss of skeletal muscle mass, while traditional nutritional support can not be completely reversed, which leads to continuous deterioration of functional damage, resulting in loss of weight, immune function and resistance to cancer treatment, which is a common complication of cancer patients and the main cause of death. At the same time, when the cancer patients receive active treatment such as chemotherapy, radiotherapy and others, the treatment has a certain traumatic effect, so the risk of the treatment
related complications is very high, which often leads to a decline in patient tolerance and compliance, which will affect the follow-up treatment, and even more serious may endanger the life of patients. Thus it can be seen, carcinemia and cancer treatment related complications are the two major problems that currently plaguing cancer treatment.It is highly demanded that cachexia be diagnosed, its progression be monitored and the complications of cancer treatment be predicted timely at present. As we all know, the determination of biomarkers can be used to understand the biological processes in the body, so biomarkers have unique advantages in identifying accurate, sensitive and low levels of damage. Moreover, the recognition of biomarkers’ significance in carcinemia and
its treatment related complications could facilitate the prevention of carcinemia and the adjustment of cancer treatment programs effectively.